Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERI-DYNAMIC: Teriflunomide Immune Effects in MS
NCT01863888Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label trial of teriflunomide in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in Lymphocyte subset parameters at 24 weeks. Started Oct 2013; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01863888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863888.